Biotech is an industry that uses technology to develop products that help improve the lives of people and the planet. It can include finding vaccines for diseases and enhancing agricultural processes to use less energy and more. Investing in biotech stocks is risky, but the returns can be huge. A mutual fund or exchange-traded fund (ETF) is the best way to gain exposure.
If you want to add a biotech stock to your portfolio, you should consider investing in Amgen (NASDAQ: AMGN). The company develops innovative human therapeutics for patients suffering from serious diseases. Its products are based on advanced human genetics and help uncover disease's mysteries and understand its fundamentals.
Amgen has a proven track record of developing drugs that improve health outcomes and dramatically impact people's lives. Its pharma business focuses on six areas: inflammation, cancer/haematology, bone health, cardiovascular disease, neurological disorders and nephrology.
Shares of Amgen have been up 11.79% this year, outperforming the iShares Biotechnology ETF (NYSEARCA: IBB) by over 31%. The stock yields a solid 3.7%, making it a great choice for dividend growth investors.
Amgen has been in the biotech game for decades. Its products are based on advanced gene editing technology. It is developing treatments for cystic fibrosis, Alzheimer's, Parkinson's and haemophilia. The company also has a promising financial future, according to analysts.
Ionis is a leading RNA-targeted drug discovery, and development company focused on drugs for patients with the highest unmet medical needs. It has a large pipeline of first-in-class or best-in-class drugs that have the potential to be marketable and transform patient care.
Ionis' RNA-targeted drug platform, called antisense technology, is an efficient, broadly applicable drug discovery tool that can be used to treat diseases where no other therapeutic approaches have worked. It has developed several drugs that are now in mid to late-stage development.
The company has a strong portfolio of assets in multiple disease areas, and most are in phase 3 development. Their ALS program is led by towers, which targets superoxide dismutase 1 (SOD1) and is under priority review with the potential for approval in 2023.
The company has another strong asset in the CNS, called Tominersen, which reduces the expression levels of mutated HTT in Huntington's Disease. They also have a lead asset in triglyceride-driven disease, which reduces elevated triglyceride levels. They are also working on DNA-targeted therapies, a new class that can treat disease by editing genetic information.
If you're looking for a biotech company with an excellent stock price, look no further than Exelixis. This company is a leader in oncology, focusing on developing new medicines for difficult-to-treat cancers. The company is based in Alameda, California. It has a campus-like environment with gardens, covered walkways, bike paths, and ferry access.
Exelixis has a lot of products in development, including the blockbuster cabozantinib. It's also a leader in antibody-drug conjugates, which are becoming increasingly popular as alternatives to chemotherapy for cancer patients because of their lower off-target effects and high cytotoxicity at tumour levels.
Currently, the company is testing a drug called XL092, which is being developed for metastatic colorectal cancer. This is a good target because colorectal cancer is the third-leading cause of death in the U.S. It's a disease that can be treated fairly well when caught early, but once it has metastasized, it can be very hard to treat effectively.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, including oncology, immunology, cardiovascular, and haematology. Its products include chemically synthesized or small molecule drugs and products produced from biological processes called biologics.
BMY has several drugs on the market, such as blood thinners Plavix and Eliquis and the cancer drug Opdivo. These three products account for a significant share of Bristol-Myers Squibb's revenue and could face competition soon.
On the positive side, BMY has a strong drug candidate pipeline and is leveraging its large cash stockpile to fund the development of new products. It is also a leader in the field of immuno-oncology and participates in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.
In addition to drug candidates, BMY has an extensive portfolio of commercial products that generate high sales. Among these are its blood-thinning medication Plavix, cancer drug Opdivo, and its antipsychotic Abilify. Its hepatitis C treatment Sovaldi, meanwhile, has strong sales and a competitive pricing advantage over generics.
Comments